Shares of Biogen are moving higher ahead of the FDA’s decision on its experimental Alzheimer’s medicine, aducanumab. The FDA action date for an approval decision is today. Citi analyst Mohit Bansal said last week that shares of Biogen could move to $150-$160 on rejection of aducanumab while approval could see the stock in the $400-$410 range. Biogen in premarket trading is up 3%, or $8.78, to $294.92.
next post